dl) and serum creatinine 1.6 mg/dl. Hepatic enzymes were normal. Urine was hyperchromic with increased urobilinogen concentration. She had mild haemoglobinaemia and haemoglobinuria. Coomb's test and a viral test for HbSAg, anti-Hb, Ag IgM, and anti-HCV were negative. A blood film showed polychromatophilia, poikilocytosis, Heinz bodies, bite cells, and erythrocytes with uneven distribution of haemoglobin (hemighosts) . Chest x-ray was normal. Throat swab, and blood cultures grew no organism. She received one unit of compatible blood and spiramycin was discontinued. One week after acute haemolysis, her haemoglobin was 11.6 g/dl and lactate dehydrogenase, reticulocyte count, renal and hepatic functions became normal.
Six weeks after recovery, informed consent was obtained and spiramycin re-instituted. 
Anticoagulants for venous thrombosis
Sir, Dr Tohl hopes that a major benefit of outpatient treatment of deep venous thrombosis using low-molecular-weight heparin will be to reduce bed shortages. Our initial experience of home treatment for deep vein thrombosis may challenge that view. Over the first three months of our service we anticoagulated 15 patients for deep venous thrombosis as out-patients using low-molecular-weight heparin as initial therapy. However, we identified 30 patients from the hospital inpatient computerised administration system that were treated for deep venous thrombosis as in-patients during this time. In fact, the mean number treated per week as in-patients in the three months after introduction of outpatient treatment (1.2, SD 1.0), was not significantly less than the number treated per week in the previous nine months (1.1, SD 0.9). As a result the weekly total treated (inand out-patients) was greater in the threemonth period (2.3, SD 1.4).
If 
